North Carolina Headlines

“Pulmonary Arterial Hypertension Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Arterial Hypertension Market.

The Pulmonary Arterial Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pulmonary Arterial Hypertension Pipeline Report:

• Companies across the globe are diligently working toward developing novel Pulmonary Arterial Hypertension treatment therapies with a considerable amount of success over the years.

• Pulmonary Arterial Hypertension companies working in the treatment market are Centessa Pharmaceuticals, Ribomic, Gmax Biopharm LLC., Novartis Pharmaceuticals, Cereno Scientific AB, Insmed Incorporated, Aerovate Therapeutics, Pharmosa Biopharm Inc, and others, are developing therapies for the Pulmonary Arterial Hypertension treatment

• Emerging Pulmonary Arterial Hypertension therapies in the different phases of clinical trials are- MGX292, RBM-011, GMA301, LTP001, CS1, Treprostinil Palmitil, AV-101, L606, and others are expected to have a significant impact on the Pulmonary Arterial Hypertension market in the coming years.

• In March 2025, Merck (NYSE: MRK), operating as MSD outside the U.S. and Canada, has unveiled the first results from its Phase 3 ZENITH trial assessing WINREVAIR™ (sotatercept-csrk) versus placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH), specifically those in WHO functional class III or IV with a high risk of mortality who were receiving maximum tolerated background therapy. At a median follow-up of 10.6 months (ranging from 0.3 to 26.1 months), WINREVAIR demonstrated a 76% reduction in the relative risk of major morbidity and mortality events—including all-cause death, lung transplant, and PAH-related hospitalization of ≥24 hours—compared to placebo (HR=0.24 [95% CI, 0.13–0.43]; p<0.0001). Major morbidity or mortality events occurred in 17.4% (15 of 86) of WINREVAIR-treated patients versus 54.7% (47 of 86) in the placebo group.

• In January 2025, Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced preliminary findings from its Phase 3 ZENITH trial assessing WINREVAIR™ (sotatercept-csrk) against placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH), specifically those categorized as WHO functional class III or IV and considered at high risk of mortality despite being on optimized background PAH treatment. Over a median follow-up period of 10.6 months (range: 0.3–26.1), WINREVAIR demonstrated a 76% reduction in the relative risk of major morbidity and mortality events—defined as all-cause death, lung transplant, or PAH-related hospitalization lasting 24 hours or more—compared to placebo (HR=0.24 [95% CI, 0.13–0.43]; p

• In October 2024, Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company focused on developing protein kinase inhibitors to address cardiopulmonary and neurodegenerative diseases via Abelson Tyrosine Kinase inhibition, has announced the closing of a $110 million private placement. This funding, generated through the sale of common stock and accompanying warrants, could potentially reach $275 million upon full cash exercise of the warrants, prior to deducting placement agent fees and expenses. The proceeds will support the execution of the Phase 2b ‘702’ trial for pulmonary arterial hypertension (PAH) and general corporate activities.

Pulmonary Arterial Hypertension Overview

Pulmonary Arterial Hypertension (PAH) is a rare, progressive condition characterized by high blood pressure in the arteries that carry blood from the heart to the lungs. This increased pressure puts a strain on the right side of the heart, making it harder to pump blood and leading to symptoms like shortness of breath, fatigue, chest pain, and swelling in the legs. PAH can be idiopathic, inherited, or associated with other conditions such as connective tissue diseases or congenital heart defects. While there is no cure, treatment options—including medications, oxygen therapy, and lifestyle changes—can help manage symptoms and improve quality of life.

Get a Free Sample PDF Report to know more about Pulmonary Arterial Hypertension Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight

Emerging Pulmonary Arterial Hypertension Drugs Under Different Phases of Clinical Development Include:

• MGX292: Centessa Pharmaceuticals

• RBM-011: Ribomic

• GMA301: Gmax Biopharm LLC.

• LTP001 : Novartis Pharmaceuticals

• CS1: Cereno Scientific AB

• Treprostinil Palmitil: Insmed Incorporated

• AV-101: Aerovate Therapeutics

• L606: Pharmosa Biopharm Inc

Pulmonary Arterial Hypertension Route of Administration

Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

• Molecule Type

Pulmonary Arterial Hypertension Molecule Type

Pulmonary Arterial Hypertension Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

Pulmonary Arterial Hypertension Pipeline Therapeutics Assessment

• Pulmonary Arterial Hypertension Assessment by Product Type

• Pulmonary Arterial Hypertension By Stage and Product Type

• Pulmonary Arterial Hypertension Assessment by Route of Administration

• Pulmonary Arterial Hypertension By Stage and Route of Administration

• Pulmonary Arterial Hypertension Assessment by Molecule Type

• Pulmonary Arterial Hypertension by Stage and Molecule Type

DelveInsight’s Pulmonary Arterial Hypertension Report covers around 55+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Pulmonary Arterial Hypertension product details are provided in the report. Download the Pulmonary Arterial Hypertension pipeline report to learn more about the emerging Pulmonary Arterial Hypertension therapies

Some of the key companies in the Pulmonary Arterial Hypertension Therapeutics Market include:

Key companies developing therapies for Pulmonary Arterial Hypertension are – VasThera Co Ltd, Altavant Sciences Inc, Alterras Therapeutics GmbH, United Therapeutics Corp, Chiesi Farmaceutici SpA, Gmax Biopharm LLC, Antlia Bioscience Inc, and others.

Pulmonary Arterial Hypertension Pipeline Analysis:

The Pulmonary Arterial Hypertension pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment.

• Pulmonary Arterial Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pulmonary Arterial Hypertension drugs and therapies

Pulmonary Arterial Hypertension Pipeline Market Drivers

• Rising prevalence of Pulmonary Arterial Hypertension worldwide, robust Drug pipeline and the new product combinations are some of the important factors that are fueling the Pulmonary Arterial Hypertension Market.

Pulmonary Arterial Hypertension Pipeline Market Barriers

• However, high cost associated with the treatment of Pulmonary Arterial Hypertension, lack of awareness among people in developing countries and other factors are creating obstacles in the Pulmonary Arterial Hypertension Market growth.

Scope of Pulmonary Arterial Hypertension Pipeline Drug Insight

• Coverage: Global

• Key Pulmonary Arterial Hypertension Companies: Centessa Pharmaceuticals, Ribomic, Gmax Biopharm LLC., Novartis Pharmaceuticals, Cereno Scientific AB, Insmed Incorporated, Aerovate Therapeutics, Pharmosa Biopharm Inc, and others

• Key Pulmonary Arterial Hypertension Therapies: MGX292, RBM-011, GMA301, LTP001, CS1, Treprostinil Palmitil, AV-101, L606, and others

• Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies

• Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers

Request for Sample PDF Report for Pulmonary Arterial Hypertension Pipeline Assessment and clinical trials

Table of Contents

1. Pulmonary Arterial Hypertension Report Introduction

2. Pulmonary Arterial Hypertension Executive Summary

3. Pulmonary Arterial Hypertension Overview

4. Pulmonary Arterial Hypertension- Analytical Perspective In-depth Commercial Assessment

5. Pulmonary Arterial Hypertension Pipeline Therapeutics

6. Pulmonary Arterial Hypertension Late Stage Products (Phase II/III)

7. Pulmonary Arterial Hypertension Mid Stage Products (Phase II)

8. Pulmonary Arterial Hypertension Early Stage Products (Phase I)

9. Pulmonary Arterial Hypertension Preclinical Stage Products

10. Pulmonary Arterial Hypertension Therapeutics Assessment

11. Pulmonary Arterial Hypertension Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pulmonary Arterial Hypertension Key Companies

14. Pulmonary Arterial Hypertension Key Products

15. Pulmonary Arterial Hypertension Unmet Needs

16 . Pulmonary Arterial Hypertension Market Drivers and Barriers

17. Pulmonary Arterial Hypertension Future Perspectives and Conclusion

18. Pulmonary Arterial Hypertension Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/